# First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy

> **NCT04568174** · PHASE1,PHASE2 · TERMINATED · sponsor: **Polyneuron Pharmaceuticals AG** · enrollment: 1 (actual)

## Conditions studied

- Anti-MAG Neuropathy

## Interventions

- **DRUG:** PPSGG
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04568174
- **Lead sponsor:** Polyneuron Pharmaceuticals AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-11-17
- **Primary completion:** 2021-09-23
- **Final completion:** 2021-09-23
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Data don't support further development
- **Last updated:** 2021-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04568174

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04568174, "First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04568174. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*